Clinical trials
Find cancer clinical trials
Answer up to four questions and the list narrows with you. Public ClinicalTrials.gov registry data retrieved 2026-10-16.
Guided search
Four questions, in the order the decision is made. Every answer can be changed or cleared, and the advanced filters stay available.
Cancer type
Pick the cancer type written on the diagnosis report.
Advanced filters
Search by study name, sponsor or drug, then narrow by cancer, subtype, marker, treatment, phase, country, access status and sort order.
251 of 251 studies
Cancer
All cancer types
Marker
All biomarkers
Treatment category
All categories
Studies
NCT03191149Phase 2Targeted therapy
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Lung Cancer | biomarker: EGFR | Targeted therapy
United States347 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker EGFR, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT03191149Not verified
NCT05633615Phase 2CAR-T cell therapy
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Lymphoma | biomarker: CD19 | CAR-T cell therapy, Immunotherapy, Chemotherapy
United States95 registry sites
Why this appears: Appears because it is recorded for Lymphoma, it mentions marker CD19, the treatment category is CAR-T cell therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05633615Not verified
NCT06170788Phase 3Immunotherapy
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Lung Cancer | biomarker: PD-L1 | Immunotherapy, Perawatan suportif dan paliatif
United States, Argentina, Australia +23220 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker PD-L1, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06170788Not verified
NCT06203600Phase 2 / Phase 3Combination regimen
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Stomach Cancer | biomarker: PD-L1 | Immunotherapy, Targeted therapy, Chemotherapy
United States375 registry sites
Why this appears: Appears because it is recorded for Stomach Cancer, it mentions marker PD-L1, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06203600Not verified
NCT06452277Phase 3Immunotherapy
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Lung Cancer | biomarker: HER2 | Immunotherapy, Chemotherapy
United States, Argentina, Australia +33279 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker HER2, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06452277Not verified
NCT06528301Phase 1Combination regimen
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
United States, Australia9 registry sites
Why this appears: Appears because it is recorded for Lymphoma, it mentions marker CD19.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06528301Not verified
NCT07020221Phase 1 / Phase 2Combination regimen
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Lung Cancer | biomarker: KRAS | Immunotherapy, Targeted therapy, Chemotherapy
United States, Australia15 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07020221Not verified
NCT07195695Phase 3Combination regimen
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Lung Cancer | biomarker: HER2 | Immunotherapy, Targeted therapy
United States, Argentina, Australia +25202 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker HER2, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07195695Not verified
NCT07458347Phase 1Immunotherapy
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Lung Cancer | biomarker: KRAS | Immunotherapy, Chemotherapy
United States9 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07458347Not verified
NCT07468071Phase 1 / Phase 2Targeted therapy
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Lung Cancer | biomarker: KRAS | Targeted therapy
Belgium, Canada, China +720 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Active, not recruiting
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07468071Not verified
NCT07532525Phase 1CAR-T cell therapy
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Lymphoma | biomarker: CD19 | CAR-T cell therapy
United States1 registry sites
Why this appears: Appears because it is recorded for Lymphoma, it mentions marker CD19, the treatment category is CAR-T cell therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07532525Not verified
NCT07659782Phase 2Targeted therapy
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Lung Cancer | biomarker: KRAS | Targeted therapy
United States, Australia, Puerto Rico22 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07659782Not verified
Five statuses, five different questions
- • Registry status: whether the study is listed as recruiting.
- • Site status: whether we have verified the location.
- • International access: whether patients from abroad may be accepted.
- • Verification: how recently we checked this record.
- • Patient match: an initial screen, not an eligibility decision.
Not sure where to start?
Upload a report summary so the team can review a potential match before you contact a study site.
Source: public ClinicalTrials.gov registry, retrieved 2026-10-16. International patient access and site readiness have not been verified for any listed study and are shown as unknown on each result. View sources and editorial policy.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.